The Sesderma laboratories, a firm located in Valencia, have a pioneering research project underway with the help of the Center for Industrial Technological Development and whose purpose is to improve current treatments for vitiligo and psoriasis.
It is estimated that in the world there are more than 160 million people affected by psoriasis and another 126 million people who suffer from vitiligo, and as a result of the use of nanotech, the company assures that the effectiveness of the treatments could be improved.
Researchers at the Puçol power plant are working on the development of new asset transportation systems with specific functions that ensure greater efficiency.
They point out that, with these studies -which are already in a very advanced phase- "more effective" treatments will be achieved to combat these skin conditions by developing new functionalized liposomes that overcome the limitations that exist in traditional psoriasis and vitiligo treatments.
The firm explains that it is a pioneer in the application of nanotech in the development and manufacture of its products, a technology that it has been using since 2008.
This technology allows, during the formulation process, the active ingredients to be encapsulated in liposomes that have a structure similar to that of the skin, which makes it possible to achieve higher levels of penetration and efficacy in the treatment of skin conditions.
Due to their small size, liposomes allow significant levels of penetration, efficacy and results; they have excellent tolerance thanks to their composition identical to that of cell membranes and the low concentration of active ingredients; They allow transporting active ingredients (liposoluble and water soluble) in the most selective way possible: peptides, antioxidants, vitamins, cosmetic active ingredients, etc. and enable a controlled release of the contained active ingredients, reaching their target area, and enhancing the effect of the product (prolonged release over time).
